Search





Search





Markets
/
Stocks
/
nasdaq-mrna
/

Moderna Inc

MRNA

Add to Watchlist

51.952USD

-2.398-4.41%

Market hours （ET）Quotes delayed by 15 min

20.62BMarket Cap

LossP/E TTM



Moderna Inc

51.952

-2.398-4.41%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Moderna Inc

Currency: USD Updated: 2026-05-08

Key Insights

Moderna Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 48.06.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Moderna Inc's Score

Industry at a Glance

Industry Ranking

54 / 156

Overall Ranking

148 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

1°C



Very Low

Very High

Neutral

Moderna Inc Highlights

StrengthsRisks

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Fairly Valued

The company’s latest PE is -6.68, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 313.36M shares, increasing 2.74% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 4.26K shares of this stock.

Analyst Rating

Based on 24 analysts

Hold

Current Rating

48.062

Target Price

-11.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Moderna Inc is 8.21, ranking 65 out of 156 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 389.00M, representing a year-over-year increase of 260.19%, while its net profit experienced a year-over-year increase of 38.31%.

Score

Industry at a Glance

Previous score

8.21

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Moderna Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Moderna Inc is 7.60, ranking 57 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is -6.68, which is -700.98% below the recent high of 40.13 and -72.39% above the recent low of -11.51.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 54/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Moderna Inc is 6.00, ranking 134 out of 156 in the Pharmaceuticals industry. The average price target is 28.00, with a high of 135.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 24 analysts

Hold

Current Rating

48.062

Target Price

-11.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Moderna Inc

MRNA

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Moderna Inc is 8.55, ranking 45 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 60.19 and the support level at 46.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.70

Change

1.85

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.345

Neutral

RSI(14)

60.557

Neutral

STOCH(KDJ)(9,3,3)

61.777

Buy

ATR(14)

3.418

Low Volatility

CCI(14)

93.477

Neutral

Williams %R

24.321

Buy

TRIX(12,20)

-0.358

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

49.138

Buy

MA10

47.856

Buy

MA20

50.637

Buy

MA50

51.599

Buy

MA100

45.884

Buy

MA200

36.121

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Moderna Inc is 7.00, ranking 47 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 78.97%, representing a quarter-over-quarter increase of 3.56%. The largest institutional shareholder is The Vanguard, holding a total of 40.46M shares, representing 10.20% of shares outstanding, with 2.05% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

26.73M

+117.58%

BlackRock Institutional Trust Company, N.A.

21.04M

+5.23%

Baillie Gifford & Co.

Star Investors

20.58M

-5.80%

State Street Investment Management (US)

16.37M

-4.34%

Two Sigma Investments, LP

15.07M

+5.38%

Capital World Investors

12.83M

Geode Capital Management, L.L.C.

9.22M

-0.32%

Boston Biotech Ventures, L.L.C.

9.21M

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Moderna Inc is 5.44, ranking 66 out of 156 in the Pharmaceuticals industry. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Moderna Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.